Zevallos says the study consisted of 66 patients and found that there were distinct genomic differences between HPV-positive smokers and non-smokers.
Jose P. Zevallos, MD, MPH, FACS, assistant professor, director of Oncologic Research, University of North Carolina School of Medicine, discusses a recent study that looked at molecular profiles determined by targeted DNA sequencing of patients with HPV-positive oropharyngeal squamous cell carcinoma (SCC). The purpose of the study was to determine if patients with HPV-positive oropharyngeal SCC, who were also smokers, had a different mutational status than non-smokers.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
2 Commerce Drive
Cranbury, NJ 08512